JP2015501146A - イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物 - Google Patents

イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物 Download PDF

Info

Publication number
JP2015501146A
JP2015501146A JP2014535165A JP2014535165A JP2015501146A JP 2015501146 A JP2015501146 A JP 2015501146A JP 2014535165 A JP2014535165 A JP 2014535165A JP 2014535165 A JP2014535165 A JP 2014535165A JP 2015501146 A JP2015501146 A JP 2015501146A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501146A5 (enExample
Inventor
デイヴィッド ギアリング
デイヴィッド ギアリング
Original Assignee
エヌヴィーアイピー プロプライエタリー リミテッド
エヌヴィーアイピー プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌヴィーアイピー プロプライエタリー リミテッド, エヌヴィーアイピー プロプライエタリー リミテッド filed Critical エヌヴィーアイピー プロプライエタリー リミテッド
Publication of JP2015501146A publication Critical patent/JP2015501146A/ja
Publication of JP2015501146A5 publication Critical patent/JP2015501146A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
JP2014535165A 2011-10-13 2012-10-12 イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物 Pending JP2015501146A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546865P 2011-10-13 2011-10-13
US61/546,865 2011-10-13
PCT/GB2012/052532 WO2013054127A1 (en) 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto

Publications (2)

Publication Number Publication Date
JP2015501146A true JP2015501146A (ja) 2015-01-15
JP2015501146A5 JP2015501146A5 (enExample) 2015-12-03

Family

ID=47023030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535165A Pending JP2015501146A (ja) 2011-10-13 2012-10-12 イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物

Country Status (7)

Country Link
US (1) US20140294819A1 (enExample)
EP (1) EP2766391A1 (enExample)
JP (1) JP2015501146A (enExample)
AU (1) AU2012322445B2 (enExample)
CA (1) CA2851758A1 (enExample)
HK (1) HK1201281A1 (enExample)
WO (1) WO2013054127A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021066134A1 (ja) 2019-10-03 2021-04-08 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
CA3014461C (en) 2016-02-18 2023-02-28 Elanco Us Inc. Chimeric canine anti-cd20 antibody
US11673961B2 (en) 2018-02-20 2023-06-13 Memorial Sloan Kettering Cancer Center Anti-CD20 antibody and uses thereof
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
JP7671275B2 (ja) * 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
WO2022263864A1 (en) * 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
AU2023379469A1 (en) * 2022-11-15 2025-05-22 Purdue Research Foundation Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005006583A (ja) * 2003-06-20 2005-01-13 Nippon Inst For Biological Science イヌ化抗体の作成方法および使用
JP2005514063A (ja) * 2001-12-21 2005-05-19 イデックス ラボラトリーズ インコーポレイテッド イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
WO2006007202A2 (en) * 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
WO2009088065A1 (ja) * 2008-01-11 2009-07-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト化抗ヒトα９インテグリン抗体
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514063A (ja) * 2001-12-21 2005-05-19 イデックス ラボラトリーズ インコーポレイテッド イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
JP2005006583A (ja) * 2003-06-20 2005-01-13 Nippon Inst For Biological Science イヌ化抗体の作成方法および使用
WO2006007202A2 (en) * 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
WO2009088065A1 (ja) * 2008-01-11 2009-07-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト化抗ヒトα９インテグリン抗体
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DARBES, J. ET AL.: ""Evaluation of the cross-reactivity between human and feline or canine leucocyte antigens using comm", J. VET. DIAGN. INVEST., vol. 9, no. 1, JPN6016034353, January 1997 (1997-01-01), pages 94 - 97, ISSN: 0003399893 *
山元哲、外７名: "「イヌパルボウィルスに対するイヌ化抗体の作製」", 日本獣医学会学術集会講演要旨集, vol. 142, JPN6016034354, 31 August 2006 (2006-08-31), pages 93, ISSN: 0003399894 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021066134A1 (ja) 2019-10-03 2021-04-08 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
US12534535B2 (en) 2019-10-03 2026-01-27 Nippon Zenyaku Kogyo Co., Ltd. Monoclonal antibody or antibody fragment against canine CD20

Also Published As

Publication number Publication date
CA2851758A1 (en) 2013-04-18
HK1201281A1 (en) 2015-08-28
EP2766391A1 (en) 2014-08-20
NZ623644A (en) 2015-03-27
AU2012322445B2 (en) 2016-12-15
AU2012322445A1 (en) 2014-04-24
WO2013054127A1 (en) 2013-04-18
US20140294819A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
US20240218076A1 (en) Therapeutic antibodies
JP7705873B2 (ja) Ｐｖｒｉｇ結合タンパク質及びその医薬用途
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN106029695B (zh) 拮抗性抗犬pd-1抗体
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
US20160208003A1 (en) Antibodies
AU2012322445B2 (en) Canine/feline CD20 binding epitope and compositions for binding thereto
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
WO2019141268A1 (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
TWI714895B (zh) 抗csf-1r抗體、其抗原結合片段及其醫藥用途
JP2024530036A (ja) 抗体Ｆｃバリアント
WO2017122666A1 (ja) 抗Ｍｙｌ９抗体
KR20240021959A (ko) 항개 cd20 항체
NZ623644B2 (en) Canine/feline cd20 binding epitope and compositions for binding thereto
HK1262617B (en) Obinutuzumab variants having altered cell death induction
MX2013013911A (es) Anticuerpos terapeuticos.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151007

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170508